Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma ( eb site atwww.accentia.net. Forward-...)

HOME >> MEDICINE >> TECHNOLOGY

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

eb site at www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Biovest International, Inc., New York, NY
Steven Arikian, MD
Chairman and Chief Executive Officer
212-686-4100 ext 8640

Page: 1 2 3 4 5
Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

Post Your Comments:

(Date:11/25/2009)...LOVELAND, Colo., Nov. 25 ...rovider of advanced diagnostic and specialty pro...agreements with Roche Diagnostics Corporation for ...nsumables for the veterinary market. ,, (Log...HESKALOGO ) ,, "Heska and Roche share the same ...

(Date:11/25/2009)...INCETON, N.J., Nov. 25 P... pharmaceutical company committed to discovering, ...t viral infections, reported financial results for...ember 30, 2009 Pharmasset held $58.4 million in ca...,, Pipeline Update and 2009 Highlights ,, ...

(Date:11/25/2009)...CAGO and STAFA, Switzerland, Nov. 25 /PRNewswire/ ...acturer of innovative hearing solutions, presented... Conference, focusing on the special needs of the ...leading experts in aging and audiology from around...veryday with older people with hearing loss for an...

[0] Heska Announces Supply Agreement With Roche Diagnostics [0] Pharmasset Reports Fiscal Year End 2009 Financial Results [0] Phonak Successfully Hosts Hearing Care for Adults 2009 Conference

..., Belgium, March 28, 2007,/PRNewswire-FirstCall/ -... results of a sample collection study aimed at,ide...aid in the,assessment for risk of sepsis progressi...d therapeutic options. Clinical investigator,Eman...or of,research at the department of emergency medi...

...3, the World,s First Commercial Vaccine,for Travel...ly,Completes Phase I Clinical Trials , ,Trial conf... , ODENSE, Denmark, March 28, 2007 -ACE BioScience...to announce the successful,completion of Phase I c...world,s first commercial vaccine for Travellers,D...

Other Medicine Technology:Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 2 Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 3 Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 4 Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 5 Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2 Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3 Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4

Biosite Reports on Presentation of Preliminary Data From Sepsis,Program Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

(Date:11/27/2009)...e/ - Uploadable USB pedometers may be new, but the...ination of advanced accelerometer functionality an...ncern over the accuracy of self-reported data. It,...oved participation in a fitness program. ,, Cor...suppliers to integrate this technology. "Our healt...

(Date:11/27/2009)...ov. 27 Team Garmin-Slipstream, the...d to ethical sporting and developing the next gene...it will become Team Garmin-Transitions with the ad...the team. Transitions Optical is the world,s leadi...most advanced photochromic technology in the wides...

(Date:11/27/2009)...27 Allrecipes.com , the world,s...raffic numbers, with more than 2.8 million visitor...icture of what was served on the biggest food holi...2009 weighed in at 2,225 calories per serving, a 5...g to the Allrecipes site, Sweet Potato Pie I sto...

(Date:11/26/2009)... -- With cold and flu season upon us, it,s more im...rol the spread of infections and avoid illness. ,...elves healthy, but to avoid transmitting illness i...ertified in infection-control), nursing director f...spital for Special Surgery (HSS) in Manhattan. ,...

(Date:11/26/2009)...nal rollercoaster, study finds , , THURS...factor meets the jubilant sports fan. , A new s...who root for the winning team -- enjoy the greates...nd victory was in doubt, producing feelings of wor...giving weekend as you,re glued to the TV set, watc...

Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2 Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3 Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4 Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2 Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3 Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4 Health News:Watching the Nail-Biting Big Game Hurts So Good 2 Health News:Watching the Nail-Biting Big Game Hurts So Good 3

[0] New USB technology adds accountability and convenience to wellness programs [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories [1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use [0] Watching the Nail-Biting Big Game Hurts So Good

...SAN FRANCISCO, Calif., Jan. 30 Onmark, a leading,...ommunity-based practices,and a McKesson Specialty ...ted Quality (IQ) Program with the goal of helping ... Lynx,Mobile(TM) technology platform, helps practi...

...TER, Pa., Jan. 30 Members of Highmark,s,FreedomBl...njoy increased,health care options. Effective imme...es will be covered at Heart of Lancaster and Lanca... with Medicare in,the surrounding areas," said J. ...

..., Ohio, Jan. 30 STERIS Corporation,(NYSE: STE ) ...008 third,quarter ended December 31, 2007. Fiscal ... million compared with $299.0 million in the third... compared with net income of $21.3 million, or $0....

...port predicts obesity could cost state an addition...y by 2020, EAGAN, Minn., Jan. 30 Less than one q...ight by 2020 according to a new,report issued by B...A Portrait of Two Minnesotas, highlights the fact ...

...SAN FRANCISCO, Calif., Jan. 30 Anesiva,Inc. (Nasd...ompleted the,hiring and deployment of its hospital...roduction of Anesiva,s FDA-approved Zingo(TM) (lid...team with substantial,hospital sales experience to...

...L, Wash, Jan. 30 Cardiac Science,Corporation (Nas...diagnosis,resuscitation, rehabilitation, and infor...e contracts secured by its corporate accounts sale...ndreds,of locations worldwide., (Logo: http:/...

Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives Heart of Lancaster and Lancaster Regional Join Highmark Blue Shield Medicare Advantage Network STERIS Corporation Announces Fiscal 2008 Third Quarter Results Minnesotans' Health Stuck in Idle From Inactivity, Unhealthy Eating Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)Cardiac Science Wins Major Corporate AED Deployment Contracts

Sterilized TowerPack Refill System D200

Finntip Wide 10-200ul, Sterile

Finntip 200 Ext (Sterile)

MBP 200MicroPoint Design

Medicine Products:

Sterilized TowerPack Refill System D200 Finntip Wide 10-200ul, Sterile Finntip 200 Ext (Sterile)MBP 200MicroPoint Design

( eb site atwww.accentia.net. Forward-...)Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma,Health